Effect of topiroxostat on diabetic nephropathy in patients with type 2 diabetes mellitus

Effect of topiroxostat on diabetic nephropathy in patients with type 2 diabetes mellitus - Effect of topiroxostat on diabetic nephropathy in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038238

Enrollment

Registered

2019-10-08

Start date

2019-10-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus, hyperuricemia

Interventions

topiroxostat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.type 2 diabetes patients who have never used antihypeuricemics 2.UA>7.0mg/dL(patients who have experienced gout or have gout nodules) or UA>=8.0mg/dL(patients with asymptomatic hyperuricemia) 3.blood pressure<140/90mmHg 4.eGFR>=30mL/min/1.73m2 5.HbA1c<10%

Exclusion criteria

Exclusion criteria: 1.patients with pregnancy 2.patients with severe infection or trauma, or under surgery 3.patients who have alcohol-induced liver injury 4.patients whose general conditions are seriously ill 5.patients who are allergic to antihyperuricemics 6.patients with serious commodities or who are judged not to be suitable for this study

Design outcomes

Primary

Measure	Time frame
changes in urine albumin-to-creatinine ratio(24 weeks apart)	—

Secondary

Measure	Time frame
blood pressure, eGFR, serum uric acid, AST, ALT, adverse event	—

Countries

Japan

Contacts

Public ContactUdai Nakamura

Kyushu University hospital Department of Nephrology, Hypertension, and Strokology

uday@intmed2.med.kyushu-u.ac.jp092-642-5256

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026